NASDAQ: NXLNexalin Technology Inc Stock
$0.47+0.01 (+2.17%)
Updated Jun 11, 2026
NXL Price
$0.47
Fair Value Price
-$0.29
Market Cap
$9.71M
52 Week Low
$0.31
52 Week High
$2.00
P/E
-1x
P/B
3.37x
P/S
25.06x
PEG
N/A
Dividend Yield
N/A
Revenue
$275.58k
Earnings
-$8.33M
Gross Margin
82%
Operating Margin
-3,022.94%
Profit Margin
-3,022.9%
Debt to Equity
0.28
Operating Cash Flow
-$5M
Beta
1.34
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NXL Overview
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NXL's potential to beat the market
- NXL doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
NXL
RankedUnranked of 94
RankedUnranked of 94
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.68 | A | |
| $37.61 | A | |
| $26.35 | A |
Be the first to know about important NXL news, forecast changes, insider trades & much more!
NXL News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NXL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NXL ($0.47) is overvalued by 263.49% relative to our estimate of its Fair Value price of -$0.29 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NXL ($0.47) is not significantly undervalued (263.49%) relative to our estimate of its Fair Value price of -$0.29 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NXL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NXL due diligence checks available for Premium users.
Valuation
NXL fair value
Fair Value of NXL stock based on Discounted Cash Flow (DCF)
Price
$0.47
Fair Value
-$0.29
Undervalued by
262.80%
NXL ($0.47) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NXL ($0.47) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NXL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NXL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1x
Industry
20.69x
Market
13.95x
NXL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.37x
Industry
2.98x
NXL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NXL's financial health
Profit margin
Revenue
$15.0k
Net Income
-$2.1M
Profit Margin
-14,025.7%
NXL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NXL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.7M
Liabilities
$808.4k
Debt to equity
0.28
NXL's short-term assets ($3.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NXL's short-term assets ($3.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NXL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.7M
Investing
$1.5M
Financing
$756.4k
NXL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NXL vs Medical Device Stocks
Nexalin Technology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.